Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed

DOI10.1002/BIMJ.201700241MaRDI QIDQ4967100zbMATH OpenOpenAlexWikidataFDO

Authors Stella Preussler, Marietta Kirchner, Meinhard Kieser

Publication date 2 July 2019

Published in Biometrical Journal (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1002/bimj.201700241

zbMATH Keywords

drug development programoptimizationphase II/IIIprobability of successsample size

Mathematics Subject Classification ID

Sampling theory, sample surveys (62D05) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Approximately optimal designs for phase II clinical studies
• A Bayesian decision approach for sample size determination in phase II trials
• Theory of drug development
• Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
• Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies

Cited in

(2)

• The estimated and theoretical assurances and the probabilities of launching a phase III trial
• drugdevelopR

This page was built for publication: Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4967100)